Research programme: chimeric antigen receptor T cell therapeutics - Mustang Bio

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - Mustang Bio

Alternative Names: MB-106; MB-106 CD20 CAR - Mustang Bio

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD20 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Oct 2017 UMass Medicine Science Park and Mustang bio entered into an agreement to support the clinical development and commercialisation of CAR T therapies
  • 01 Oct 2017 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral)
  • 14 Sep 2017 Mustang Bio plans a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top